Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206284 · ClinicalTrials.gov registry record · Phase 2
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,400
- Enrollment target
NCT00206284: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00206284 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 1,400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (953% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206284, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate the safety and tolerability of AZD0865.
Interventions
- DRUG AZD0865
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00206284 record still lists
NCT00206284 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (953% higher).
The record links to 0 conditions, and to 1 intervention - of which AZD0865 is the first listed.
NCT00206284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206284 about?
NCT00206284 is a clinical study titled "A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.". The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate the safety and tolerability of AZD0865.
What is the current status of trial NCT00206284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2004-05. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00206284?
The interventions under investigation include: AZD0865 (DRUG).
Who is sponsoring clinical trial NCT00206284?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206284's enrollment target sits among peer trials
1,400 12th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia